Radiopharmaceutical firm IBA Molecular has launched a new appropriate use initiative for oncologic imaging with PET/CT.
The effort will educate the medical community about the impact of PET/CT imaging on patient care management via online and onsite webinars, roundtables, PET education resources, and more; will clarify with referrers the rules for expanded coverage of FDG oncologic PET/CT imaging from the U.S. Centers for Medicare and Medicaid Services (CMS); and will facilitate claims processing for PET/CT, the company said.
